Regulation M Compliance. The Company and its controlled affiliates have not taken, directly or indirectly, any action designed to or that has constituted or that could reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company in connection with the offering of the Securities.
Appears in 9 contracts
Samples: Securities Purchase Agreement (Heron Therapeutics, Inc. /De/), Securities Purchase Agreement (Sonendo, Inc.), Securities Purchase Agreement (Heron Therapeutics, Inc. /De/)
Regulation M Compliance. The Company has not, and to its controlled affiliates have not knowledge no one acting on its behalf has taken, directly or indirectly, any action designed to or that has constituted or that could reasonably be expected to cause or to result in the stabilization or manipulation of the price of any security of the Company in connection with a violation of Regulation M under the offering of the SecuritiesExchange Act.
Appears in 8 contracts
Samples: Securities Purchase Agreement (Cardiff Oncology, Inc.), Securities Purchase Agreement (Trillium Therapeutics Inc.), Securities Purchase Agreement (Kura Oncology, Inc.)
Regulation M Compliance. The Company and its controlled affiliates have has not taken, directly or indirectly, any action designed to or that has constituted or that could reasonably be expected to cause or result in the any stabilization or manipulation of the price of any security of the Company in connection with the offering of the Securities.
Appears in 6 contracts
Samples: Securities Purchase Agreement (Medicinova Inc), Securities Purchase Agreement (Hipcricket, Inc.), Securities Purchase Agreement (Oncothyreon Inc.)
Regulation M Compliance. The Company and its controlled affiliates have has not taken, directly or indirectly, any action designed to or that has constituted or that could would reasonably be expected to cause or result in the stabilization or manipulation of any of its securities to facilitate the price of any security sale or resale of the Company in connection with the offering of the SecuritiesPurchased Shares.
Appears in 6 contracts
Samples: Securities Purchase Agreement (Summit Therapeutics Inc.), Securities Purchase Agreement (Summit Therapeutics Inc.), Securities Purchase Agreement (Summit Therapeutics Inc.)
Regulation M Compliance. The Company and its controlled affiliates have has not taken, directly or indirectly, any action designed to or that has constituted or that could would reasonably be expected to cause or result in the stabilization or manipulation of the price of any security the Common Stock to facilitate the sale or resale of the Company in connection with the offering of the SecuritiesShares.
Appears in 5 contracts
Samples: Stock Purchase Agreement (Neurocrine Biosciences Inc), Stock Purchase Agreement (Neurocrine Biosciences Inc), Stock Purchase Agreement (Arvinas, Inc.)
Regulation M Compliance. The Company and its controlled affiliates have has not taken, directly or indirectly, any action designed to or that has constituted or that could would reasonably be expected to cause or result in the stabilization or manipulation of the price of any security the Common Shares to facilitate the sale or resale of the Company in connection with the offering of the SecuritiesPurchased Shares.
Appears in 4 contracts
Samples: Share Purchase Agreement (Xenon Pharmaceuticals Inc.), Share Purchase Agreement (Xenon Pharmaceuticals Inc.), License and Collaboration Agreement (Xenon Pharmaceuticals Inc.)
Regulation M Compliance. The Company and its controlled affiliates have has not taken, directly or indirectly, any action designed to or that has constituted or that could reasonably be expected to cause or to result in the stabilization or manipulation of the price of any security of the Company in connection with to facilitate the offering sale or resale of any of the SecuritiesShares.
Appears in 4 contracts
Samples: Stock Purchase Agreement (Intellia Therapeutics, Inc.), Stock Purchase Agreement (Alnylam Pharmaceuticals, Inc.), Stock Purchase Agreement (Regeneron Pharmaceuticals, Inc.)
Regulation M Compliance. The Company and its controlled affiliates have has not taken, directly or indirectly, any action designed to or that has constituted or that could would reasonably be expected to cause or result in the stabilization or manipulation of any of its securities to facilitate the price of any security sale or resale of the Company in connection with the offering of the SecuritiesNote.
Appears in 2 contracts
Samples: Note Purchase Agreement (Summit Therapeutics Inc.), Note Purchase Agreement (Summit Therapeutics Inc.)
Regulation M Compliance. The Company and its controlled affiliates Affiliates have not not, and to the Company’s knowledge no other Person acting on its or their behalf has taken, directly or indirectly, any action designed to or that has constituted or that could reasonably be expected to cause or to result in the stabilization or manipulation of the price of any security of the Company in connection with the offering Company, including under Regulation M of the SecuritiesExchange Act.
Appears in 2 contracts
Samples: Securities Purchase Agreement (Comera Life Sciences Holdings, Inc.), Securities Purchase Agreement (Comera Life Sciences Holdings, Inc.)
Regulation M Compliance. The Company and its controlled affiliates have has not taken, directly or indirectly, any action designed to or that has constituted would constitute or that could might reasonably be expected to cause or result in in, under the Exchange Act or otherwise, stabilization or manipulation of the price of any security of the Company in connection with to facilitate the offering sale or resale of the Securities.
Appears in 2 contracts
Samples: Securities Purchase Agreement (Hecla Mining Co/De/), Securities Purchase Agreement (Hecla Mining Co/De/)
Regulation M Compliance. The Company and its controlled affiliates have not taken, directly or indirectly, any action designed to or that has constituted or that could reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company in connection with the offering of the SecuritiesShares.
Appears in 1 contract
Samples: Stock Purchase Agreement (Alpine Immune Sciences, Inc.)
Regulation M Compliance. The Company and its controlled affiliates have has not taken, directly or indirectly, any action designed to or that has constituted or that could would be reasonably be expected to cause or result in the stabilization or manipulation of the price of the Common Shares or ADSs or any security other “reference security” (as defined in Rule 100 of Regulation M under the Company in connection with the offering of the SecuritiesExchange Act.
Appears in 1 contract
Samples: Securities Purchase Agreement (XINHUA SPORTS & ENTERTAINMENT LTD)
Regulation M Compliance. The Company and its controlled affiliates have has not taken, directly or indirectly, any action designed to or that has constituted would constitute or that could would reasonably be expected to cause or result in in, under the Exchange Act or otherwise, stabilization or manipulation of the price of any security of the Company in connection with to facilitate the offering sale or resale of the SecuritiesShares.
Appears in 1 contract
Regulation M Compliance. The Company and its controlled affiliates have not taken, directly or indirectly, any action designed to or that has constituted or that could reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company in connection with the offering of the SecuritiesPlacement Shares.
Appears in 1 contract
Samples: Alpine Immune Sciences, Inc.
